Fierce Biotech January 22, 2024
After slimming down its product suite with the sale last year of its robotic surgery system, Accelus is doubling down on its remaining offerings.
The company is zeroing in on its flagship FlareHawk interbody fusion system, as well as the Toro system, both of which are expandable spine implants used to treat degenerative disc disease. It plans to expand its R&D efforts around both systems—plans that will now be helped along by a new bout of funding.
Accelus has picked up $20 million in the form of a debt facility from life sciences-focused credit partner Symbiotic Capital, it announced last week.
The investment from Symbiotic “is a testament to the growth potential of Accelus’s technology and our vision for the...
Today's Sponsors
Today's Sponsor